Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.55 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978462 | 0.91 | HSP90AB1 (0.44) | KDM2BHSP90AB1HPGDKDM4E | |
| SCHEMBL4976453 | 0.89 | HTT (0.56) | HSP90AB1HPGDL3MBTL1L3MBTL3HTT | |
| SCHEMBL4979083 | 0.89 | ALDH1A1 (0.56) | KDM2BMEN1KMT2AHSP90AB1L3MBTL1 | |
| SCHEMBL4979058 | 0.89 | KDM2B (0.53) | KDM2BGBA1MEN1KMT2AHSP90AB1 | |
| SCHEMBL4976359 | 0.89 | HSP90AB1 (0.52) | KDM2BHSP90AB1L3MBTL1L3MBTL3KDM4E | |
| SCHEMBL4976742 | 0.89 | KDM2B (0.57) | KDM2BMEN1KMT2AHSP90AB1HPGD | |
| SCHEMBL4976299 | 0.88 | HSP90AB1 (0.48) | KDM2BKMT2AHSP90AB1HPGDL3MBTL1 | |
| SCHEMBL4975212 | 0.87 | KDM2B (0.47) | KDM2BMEN1KMT2AHSP90AB1HPGD | |
| SCHEMBL4976704 | 0.87 | POLB (0.47) | KDM2BMEN1KMT2AHSP90AB1HPGD | |
| SCHEMBL4978537 | 0.86 | HSP90AB1 (0.52) | MEN1KMT2AHSP90AB1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007146122-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | KDM2B 1937/4885GBA1 3687/4885MEN1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.